Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)(SUNRISELMS) | terminated | Phase 2 / Phase 3 | 359 | PTC TherapeuticsINDUSTRY | 12 | Jun 13, 2025 | clinicaltrials |
| NCT02010957 | Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia(FAMIAN) | terminated | Phase 3 | 85 | Wuerzburg University HospitalOTHER | 1 | Jun 10, 2025 |
| clinicaltrials |
| NCT06108739 | ATG Plus Low-dose PT-Cy for GVHD Prevention | terminated | Phase 3 | 66 | Peking University People's HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04856787 | A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC | terminated | Phase 2 / Phase 3 | 62 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | terminated | Phase 3 | 1,040 | Swiss Cancer InstituteOTHER | 4 | May 16, 2025 | clinicaltrials |
| NCT04427072 | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-III) | terminated | Phase 3 | 22 | Novartis PharmaceuticalsINDUSTRY | 18 | May 16, 2025 | clinicaltrials |
| NCT02807181 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma(SIRCCA) | terminated | Phase 2 / Phase 3 | 89 | Sirtex MedicalINDUSTRY | 8 | May 9, 2025 | clinicaltrials |
| NCT05930938 | Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer(XXL_2022-01) | terminated | Phase 3 | 19 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT05179239 | A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer | terminated | Phase 3 | 31 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT03016130 | Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) | terminated | Phase 3 | 217 | University of FloridaOTHER | 1 | Apr 7, 2025 | clinicaltrials |
| NCT05079230 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia(ENHANCE-3) | terminated | Phase 3 | 378 | Gilead SciencesINDUSTRY | 20 | Apr 4, 2025 | clinicaltrials |
| NCT04786964 | Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC(CONTERNO) | terminated | Phase 3 | 25 | Checkpoint Therapeutics, Inc.INDUSTRY | 8 | Apr 2, 2025 | clinicaltrials |
| NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | terminated | Phase 2 / Phase 3 | 70 | Mateon TherapeuticsINDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT00448240 | Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 6 | Henry Ford Health SystemOTHER | 0 | Mar 18, 2025 | clinicaltrials |
| NCT03746054 | Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality(PALERMO) | terminated | Phase 3 | 80 | University Hospital, AngersOTHER_GOV | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04316013 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial | terminated | Phase 3 | 254 | Peter MacCallum Cancer Centre, AustraliaOTHER | 3 | Mar 14, 2025 | clinicaltrials |
| NCT04421547 | Efficacy of Letrozole in Recurrent Ovarian Cancer(MITO32) | terminated | Phase 3 | 86 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04901988 | Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION(DETECTION) | terminated | Phase 2 / Phase 3 | 8 | The Christie NHS Foundation TrustOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04709380 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | terminated | Phase 3 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT00051545 | Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma | terminated | Phase 3 | 608 | LEO PharmaINDUSTRY | 5 | Feb 25, 2025 | clinicaltrials |
| NCT03936933 | Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer | terminated | Phase 3 | 6 | Eurofarma Laboratorios S.A.INDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03013946 | Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy(PREPARE) | terminated | Phase 3 | 121 | AIO-Studien-gGmbHOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02231164 | LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research | terminated | Phase 3 | 12 | Boehringer IngelheimINDUSTRY | 3 | Feb 13, 2025 | clinicaltrials |
| NCT05664217 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | terminated | Phase 2 / Phase 3 | 15 | Nektar TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03862170 | Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer(BRP30) | terminated | Phase 3 | 158 | CR-CSSS Champlain-Charles-Le MoyneOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04778397 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated(ENHANCE-2) | terminated | Phase 3 | 258 | Gilead SciencesINDUSTRY | 15 | Feb 5, 2025 | clinicaltrials |
| NCT05181540 | A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation(E-CELERATE) | terminated | Phase 3 | 130 | Angiocrine BioscienceINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT02887521 | Pulmonary Rehabilitation Before Lung Cancer Resection | terminated | Phase 3 | 9 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 3, 2025 | clinicaltrials |
| NCT03839940 | Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer(MIST) | terminated | Phase 3 | 39 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04979442 | Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma(MANTRA) | terminated | Phase 3 | 175 | Rain Oncology IncINDUSTRY | 15 | Jan 14, 2025 | clinicaltrials |
| NCT01167725 | Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer | terminated | Phase 3 | 340 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04410042 | Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure | terminated | Phase 3 | 15 | St. Jude Children's Research HospitalOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02612311 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia(UNITY-CLL) | terminated | Phase 3 | 603 | TG Therapeutics, Inc.INDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-4) | terminated | Phase 3 | 551 | BayerINDUSTRY | 35 | Dec 11, 2024 | clinicaltrials |
| NCT02588261 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations(SOLAR) | terminated | Phase 3 | 530 | Astellas Pharma Global Development, Inc.INDUSTRY | 23 | Dec 10, 2024 | clinicaltrials |
| NCT02867839 | Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer(RESCUE-GC) | terminated | Phase 3 | 29 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04607668 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):(PRESERVE1) | terminated | Phase 3 | 326 | G1 Therapeutics, Inc.INDUSTRY | 8 | Nov 26, 2024 | clinicaltrials |
| NCT03512756 | A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer | terminated | Phase 2 / Phase 3 | 130 | Tyme, IncINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT04745832 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | terminated | Phase 3 | 82 | MEI Pharma, Inc.INDUSTRY | 19 | Nov 4, 2024 | clinicaltrials |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A(Canopy-A) | terminated | Phase 3 | 1,382 | Novartis PharmaceuticalsINDUSTRY | 41 | Oct 9, 2024 | clinicaltrials |
| NCT03452137 | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck(IMvoke010) | terminated | Phase 3 | 406 | Hoffmann-La RocheINDUSTRY | 23 | Oct 9, 2024 | clinicaltrials |
| NCT04428333 | Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(INDUCE-4) | terminated | Phase 3 | 117 | GlaxoSmithKlineINDUSTRY | 19 | Oct 9, 2024 | clinicaltrials |
| NCT01285557 | Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial(DIGEST) | terminated | Phase 3 | 361 | Taiho Oncology, Inc.INDUSTRY | 20 | Sep 19, 2024 | clinicaltrials |
| NCT03777982 | Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT | terminated | Phase 3 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jun 13, 2025source: clinicaltrials